KRAS mutation in patients with lung cancer: A predictor for poor prognosis but not for EGFR-TKIs or chemotherapy

Annals of Surgical Oncology

Volumn 20, Issue 4, 2013, Pages 1381-1388

  Guan, Ji Lin ^a   Zhong, Wen Zhao ^a   An, She Juan ^a   Yang, Jin Ji ^a   Su, Jian ^a   Chen, Zhi Hong ^a   Yan, Hong Hong ^a   Chen, Zhi Yong ^a   Huang, Zhi Min ^a   Zhang, Xu Chao ^a   Nie, Qiang ^a   Wu, Yi Long ^a  

^a GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; K RAS PROTEIN; PROTEIN TYROSINE KINASE INHIBITOR;

ADULT; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER STAGING; COMORBIDITY; CONFERENCE PAPER; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; GENE MUTATION; HUMAN; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; METASTASIS; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; SMOKING; TREATMENT RESPONSE;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; CARCINOMA, LARGE CELL; CARCINOMA, SQUAMOUS CELL; DRUG RESISTANCE, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SMALL CELL LUNG CARCINOMA; SURVIVAL RATE;

EID: 84875211965     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-012-2754-z     Document Type: Conference Paper

References (34)

1. W Pao N Girard 2011 New driver mutations in non-small-cell lung cancer Lancet Oncol. 12 175 180 21277552 10.1016/S1470-2045(10)70087-5 1:CAS:528:DC%2BC3MXht12ns74%3D
2. JH Schiller D Harrington CP Belani, et al. 2002 Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer N Engl J Med. 346 92 98 11784875 10.1056/NEJMoa011954 1:CAS:528:DC%2BD38Xkt1OlsQ%3D%3D
3. GV Scagliotti P Parikh J von Pawel, et al. 2008 Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer J Clin Oncol. 26 3543 3551 18506025 10.1200/JCO.2007.15.0375 1:CAS:528:DC%2BD1cXpvVWmtLg%3D
4. GJ Riely J Marks W Pao 2009 KRAS mutations in non-small cell lung cancer Proc Am Thorac Soc. 6 201 205 19349489 10.1513/pats.200809-107LC 1:CAS:528:DC%2BD1MXltlOqtLw%3D
5. TS Mok YL Wu S Thongprasert, et al. 2009 Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma N Engl J Med. 361 947 957 19692680 10.1056/NEJMoa0810699 1:CAS:528:DC%2BD1MXhtVygsbfK
6. T Mitsudomi S Morita Y Yatabe, et al. 2010 Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial Lancet Oncol. 11 121 128 20022809 10.1016/S1470-2045(09)70364-X 1:CAS:528:DC%2BC3cXhtlGgtbo%3D
7. IJ Dahabreh H Linardou F Siannis P Kosmidis D Bafaloukos S Murray 2010 Somatic EGFR mutation and gene copy gain as predictive biomarkers for response to tyrosine kinase inhibitors in non-small cell lung cancer Clin Cancer Res. 16 291 303 20028749 10.1158/1078-0432.CCR-09-1660 1:CAS:528:DC%2BC3cXot1Sh
8. S Aviel-Ronen FH Blackhall FA Shepherd MS Tsao 2006 K-ras mutations in non-small-cell lung carcinoma: a review Clin Lung Cancer. 8 30 38 16870043 10.3816/CLC.2006.n.030 1:CAS:528:DC%2BD28XovFGisbk%3D
9. F Grossi M Loprevite M Chiaramondia, et al. 2003 Prognostic significance of K-ras, p53, bcl-2, PCNA, CD34 in radically resected non-small cell lung cancers Eur J Cancer. 39 1242 1250 12763212 10.1016/S0959-8049(03)00232-6 1:CAS:528:DC%2BD3sXjvFelur0%3D
10. M Huncharek J Muscat JF Geschwind 1999 K-ras oncogene mutation as a prognostic marker in non-small cell lung cancer: a combined analysis of 881 cases Carcinogenesis. 20 1507 1510 10426799 10.1093/carcin/20.8.1507 1:CAS:528:DyaK1MXltlKgu78%3D
11. T Woo K Okudela T Yazawa, et al. 2009 Prognostic value of KRAS mutations and Ki-67 expression in stage I lung adenocarcinomas Lung Cancer. 65 355 362 19162366 10.1016/j.lungcan.2008.11.020
12. L Bonanno M Schiavon G Nardo, et al. 2010 Prognostic and predictive implications of EGFR mutations, EGFR copy number and KRAS mutations in advanced stage lung adenocarcinoma Anticancer Res. 30 5121 5128 21187500
13. YT Kim TY Kim DS Lee, et al. 2008 Molecular changes of epidermal growth factor receptor (EGFR) and KRAS and their impact on the clinical outcomes in surgically resected adenocarcinoma of the lung Lung Cancer. 59 111 118 17904685 10.1016/j.lungcan.2007.08.008
14. C Mascaux N Iannino B Martin, et al. 2005 The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis Br J Cancer. 92 131 139 15597105 10.1038/sj.bjc.6602258 1:CAS:528:DC%2BD2MXhtFSjsrs%3D
15. A Kalikaki A Koutsopoulos D Hatzidaki, et al. 2010 Clinical outcome of patients with non-small cell lung cancer receiving front-line chemotherapy according to EGFR and K-RAS mutation status Lung Cancer. 69 110 115 19854533 10.1016/j.lungcan.2009.09.010
16. C Camps E Jantus-Lewintre A Cabrera, et al. 2011 The identification of KRAS mutations at codon 12 in plasma DNA is not a prognostic factor in advanced non-small cell lung cancer patients Lung Cancer. 72 365 369 21074889 10.1016/j.lungcan.2010.09.005
17. T Kosaka Y Yatabe R Onozato H Kuwano T Mitsudomi 2009 Prognostic implication of EGFR, KRAS, and TP53 gene mutations in a large cohort of Japanese patients with surgically treated lung adenocarcinoma J Thorac Oncol. 4 22 29 19096302 10.1097/JTO.0b013e3181914111
18. RJ Kelly A Rajan J Force, et al. 2011 Evaluation of KRAS mutations, angiogenic biomarkers, and DCE-MRI in patients with advanced non-small-cell lung cancer receiving sorafenib Clin Cancer Res. 17 1190 1199 21224376 10.1158/1078-0432.CCR-10-2331 1:CAS:528:DC%2BC3MXis1eit78%3D
19. Y Loriot P Mordant E Deutsch KA Olaussen JC Soria 2009 Are RAS mutations predictive markers of resistance to standard chemotherapy? Nat Rev Clin Oncol. 6 528 534 19597509 10.1038/nrclinonc.2009.106 1:CAS:528:DC%2BD1MXhtVKjsrjK
20. PJ Roberts TE Stinchcombe CJ Der MA Socinski 2010 Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy? J Clin Oncol. 28 4769 4777 20921461 10.1200/JCO.2009.27.4365 1:CAS:528:DC%2BC3cXhsF2rtLzF
21. W Pao TY Wang GJ Riely, et al. 2005 KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib PLoS Med. 2 e17 15696205 10.1371/journal.pmed.0020017
22. H Linardou IJ Dahabreh D Kanaloupiti, et al. 2008 Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer Lancet Oncol. 9 962 972 18804418 10.1016/S1470-2045(08)70206-7 1:CAS:528:DC%2BD1cXhtFOmurvJ
23. C Mao LX Qiu RY Liao, et al. 2010 KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: a meta-analysis of 22 studies Lung Cancer. 69 272 278 20022659 10.1016/j.lungcan.2009.11.020
24. DM Jackman VA Miller LA Cioffredi, et al. 2009 Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials Clin Cancer Res. 15 5267 5273 19671843 10.1158/1078-0432.CCR-09- 0888 1:CAS:528:DC%2BD1MXpvFeitLs%3D
25. JY Douillard FA Shepherd V Hirsh, et al. 2010 Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial J Clin Oncol. 28 744 752 20038723 10.1200/JCO.2009.24.3030 1:CAS:528:DC%2BC3cXksVyrsbY%3D
26. CQ Zhu G Da Cunha Santos K Ding, et al. 2008 Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21 J Clin Oncol. 26 4268 4275 18626007 10.1200/JCO.2007.14.8924 1:CAS:528:DC%2BD1cXhtF2it7bF
27. P Therasse SG Arbuck EA Eisenhauer, et al. 2000 New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst. 92 205 216 10655437 10.1093/jnci/92.3.205 1:STN:280:DC%2BD3c7it1Gitg%3D%3D
28. Kramer D, Thunnissen FB, Gallegos-Ruiz MI, et al. A fast, sensitive and accurate high resolution melting (HRM) technology-based assay to screen for common K-ras mutations. Cell Oncol. 2009;31(3):161-7.
29. RJ Slebos RE Kibbelaar O Dalesio, et al. 1990 K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung N Engl J Med. 323 561 565 2199829 10.1056/NEJM199008303230902 1:STN:280:DyaK3czktVemsQ%3D%3D
30. P Broermann K Junker BH Brandt, et al. 2002 Trimodality treatment in Stage III nonsmall cell lung carcinoma: prognostic impact of K-ras mutations after neoadjuvant therapy Cancer. 94 2055 2062 11932909 10.1002/cncr.10387 1:CAS:528:DC%2BD38XjsVCnsLg%3D
31. T Kosaka Y Yatabe H Endoh H Kuwano T Takahashi T Mitsudomi 2004 Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications Cancer Res. 64 8919 8923 15604253 10.1158/0008-5472.CAN- 04-2818 1:CAS:528:DC%2BD2cXhtVOmsL3P
32. Poullis M, McShane J, Shaw M, et al. Smoking status at diagnosis and histology type as determinants of long-term outcomes of lung cancer patients. Eur J Cardiothorac Surg. doi: 10.1093/ejcts/ezs464.
33. M Sonobe M Kobayashi M Ishikawa, et al. 2012 Impact of KRAS and EGFR gene mutations on recurrence and survival in patients with surgically resected lung adenocarcinomas Ann Surg Oncol. 19 Suppl 3 347 354 10.1245/s10434-011-1799-8
34. E Massarelli M Varella-Garcia X Tang, et al. 2007 KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer Clin Cancer Res. 13 2890 2896 17504988 10.1158/1078-0432.CCR-06-3043 1:CAS:528: DC%2BD2sXlt1Krs7g%3D